Pharsight

NOVARTIS AG patents facing oppositions

Top patents of NOVARTIS AG facing oppositions at the European Patent Office (EPO).

Patent Number Grant Date Patent Title Expected Expiration Date Facing Oppositions Activity Alert
EP2959894B1 12 Oct, 2022 S1p receptor modulators for treating multiple sclerosis Jun, 2027 25
EP3294283B1 08 Mar, 2023 Sacubitril-valsartan dosage regimen for treating heart failure May, 2036 16
EP3038654B1 30 Oct, 2019 New use Aug, 2034 9
EP2340828B1 15 Jul, 2020 Pharmaceutical combinations of an angiotensin receptor antagonist and a nep inhibitor Nov, 2026 8
EP3067043B1 30 Nov, 2022 Pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor Nov, 2028 6
EP3777834B1 16 Feb, 2022 Syringe May, 2033 6
EP3685826B1 03 Nov, 2021 Syringe Jan, 2033 6
EP3366283B1 01 Sep, 2021 Direct compression formulation and process Jan, 2025 6
EP2887961B1 28 Apr, 2021 Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling Aug, 2033 6
EP3033086B1 22 Sep, 2021 Combination therapy for the treatment of cancer Aug, 2034 5
EP2563903B1 21 Aug, 2019 Improved cell culture medium Apr, 2031 5
EP1983984B1 07 Mar, 2018 Tuberous sclerosis treatment Jan, 2027 4
EP3023095B2 08 Nov, 2023 Direct compression formulation and process Jan, 2025 3
EP3858405B1 05 Apr, 2023 Syringe May, 2033 3
EP3119423B1 14 Dec, 2022 Treatment of cancer using chimeric antigen receptor Mar, 2035 3
EP3283058B1 16 Nov, 2022 Ribociclib tablet Apr, 2036 3
EP3656373B1 16 Feb, 2022 Syringe Jan, 2033 3
EP2892535B1 22 Sep, 2021 Method of adjuvant cancer treatment Aug, 2033 3
EP3679922B1 28 Jul, 2021 Syringe May, 2033 3
EP3381444B1 19 May, 2021 Syringe Jan, 2033 3
EP3536310B1 28 Apr, 2021 Syringe May, 2033 3
EP3453387B1 03 Jun, 2020 Dosage regimen for a s1p receptor agonist Dec, 2029 3
EP3111954B1 03 Apr, 2019 Methods of treating ankylosing spondylitis using anti-il-17 antibodies Nov, 2031 3
EP2608784B1 19 Sep, 2018 Treatment or prevention of heart failure in a mammal receiving anti-coagulant therapy Aug, 2031 3
EP3805248B1 18 Jan, 2023 Process for concentration of antibodies and therapeutic products thereof Sep, 2025 2
EP3560498B1 17 Aug, 2022 Combination comprising an mek inhibitor and a b-raf inhibitor Oct, 2030 2
EP3541387B1 21 Apr, 2021 Dose and regimen for hdm2-p53 interaction inhibitors Nov, 2037 2
EP2654736B1 01 Jul, 2020 Novel pharmaceutical composition Dec, 2031 2
EP3127427B1 08 Jan, 2020 Methods of administration of thrombopoietin agonist compounds May, 2030 2
EP3409274B1 20 Nov, 2019 Dosage regimen for a s1p receptor agonist Dec, 2029 2
EP2869813B1 21 Nov, 2018 Syringe Jan, 2033 2
EP2567709B1 27 Dec, 2017 Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6) Oct, 2028 2
EP3124018B1 20 Dec, 2017 Oral formulations of deferasirox Mar, 2034 2
EP2651918B1 12 Jul, 2017 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine Dec, 2031 2
EP2762140B1 22 Mar, 2017 Treatment of solid brain tumours with a rapamycin derivative Feb, 2022 2
EP3618875B1 05 Apr, 2023 Combination therapy comprising a raf inhibitor and trametinib Apr, 2038 1
EP3738585B1 14 Dec, 2022 Direct compression formulation and process Jan, 2025 1
EP2307457B2 22 Jun, 2022 Stable and soluble antibodies inhibiting tnf Jun, 2029 1
EP3407945B1 04 May, 2022 Method for measuring flow features in an inhaler, inhaler and system Jan, 2037 1
EP3157571B1 24 Nov, 2021 Fatty acids and their use in conjugation to biomolecules Jun, 2035 1
EP2971094B1 15 Sep, 2021 Biomarkers associated with brm inhibition Mar, 2034 1
EP3076969B1 01 Sep, 2021 Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor Dec, 2034 1
EP2834246B1 28 Jul, 2021 Combination products with tyrosine kinase inhibitors and their use Apr, 2033 1
EP2970468B1 07 Jul, 2021 Notch2 binding molecules for treating respiratory diseases Mar, 2034 1
EP2952177B1 20 Jan, 2021 Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators Oct, 2028 1
EP3172209B1 02 Dec, 2020 Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Jul, 2035 1
EP3377618B1 18 Nov, 2020 Buffers for stabilization of lentiviral preparations Nov, 2036 1
EP3160463B1 21 Oct, 2020 Intermittent dosing of mdm2 inhibitor Jun, 2035 1
EP3199193B1 26 Aug, 2020 Method for measuring flow features in an inhaler, inhaler and system Jan, 2036 1
EP3489211B1 15 Jul, 2020 Improved methods for preparing squalene May, 2031 1
EP3045164B1 15 Apr, 2020 Aqueous pharmaceutical compositions containing borate-polyol complexes Jun, 2030 1
EP3340990B1 25 Sep, 2019 Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer Aug, 2036 1
EP3083676B1 28 Aug, 2019 Novel eukaryotic cells and methods for recombinantly expressing a product of interest Dec, 2034 1
EP2724728B1 17 Oct, 2018 Complexes of il-15 and il-15r alpha and uses thereof Jun, 2028 1
EP2558092B1 27 Jun, 2018 Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer Apr, 2031 1
EP2925299B1 06 Jun, 2018 Novel pharmaceutical composition Nov, 2033 1
EP2934515B1 04 Apr, 2018 A pharmaceutical combination comprising binimetinib Dec, 2033 1
EP2124547B1 28 Mar, 2018 Cancer treatment method Feb, 2028 1
EP2908777B1 02 Aug, 2017 System for providing an intraocular lens having an improved depth of field Dec, 2033 1
EP2234781B1 05 Jul, 2017 Method for cast molding contact lenses Dec, 2028 1
EP2783686B1 21 Jun, 2017 Combination of a rapamycin derivative and letrozole for treating breast cancer Feb, 2022 1